Latest & greatest articles for multiple sclerosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on multiple sclerosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on multiple sclerosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for multiple sclerosis

41. Information provision for people with multiple sclerosis. Full Text available with Trip Pro

Information provision for people with multiple sclerosis. People with multiple sclerosis (MS) are confronted with a number of important uncertainties concerning many aspects of the disease. These include diagnosis, prognosis, disease course, disease-modifying therapies, symptomatic therapies, and non-pharmacological interventions, among others. While people with MS demand adequate information to be able to actively participate in medical decision making and to self manage their disease, it has (...) to promote informed choice and improve patient-relevant outcomes, Further objectives were to evaluate the components and the developmental processes of the complex interventions used, to highlight the quantity and the certainty of the research evidence available, and to set an agenda for future research.For this update, we searched the Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group Specialised Register, which contains trials from CENTRAL (the Cochrane Library 2017

2018 Cochrane

42. Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study (Abstract)

Discriminative ability and clinical utility of the Timed Up and Go (TUG) in identifying falls risk in people with multiple sclerosis: a prospective cohort study To investigate discriminative ability and clinical utility of the Timed Up and Go under single- and dual-task conditions between fallers and non-fallers in multiple sclerosis (MS).Prospective cohort study.Neurology service in a tertiary hospital.Participants were 101 people with MS and Expanded Disability Status Scale score of 3-6.5 (...) -Cognitive in distinguishing fallers (person with ⩾1 fall) from non-fallers are 0.60 and 0.57, respectively, and in distinguishing multiple fallers (⩾2 falls) the values are 0.46 and 0.43. A Timed Up and Go score of ⩾9 seconds has a sensitivity of 0.82 and a specificity of 0.34 to identify fallers and a sensitivity of 0.79 and a specificity of 0.27 to identify multiple fallers. A Timed Up and Go-Cognitive score of ⩾11 seconds has a sensitivity of 0.77 and a specificity of 0.30 to identify fallers

2018 EvidenceUpdates

43. Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management Full Text available with Trip Pro

Relationship Between Physiological and Perceived Fall Risk in People With Multiple Sclerosis: Implications for Assessment and Management This study evaluated the relationship between physiological and perceived fall risk in people with multiple sclerosis (MS).Secondary analysis of data from prospective cohort studies undertaken in Australia, the United Kingdom, and the United States.Community.Ambulatory people with MS (N=416) (age 51.5±12.0 years; 73% female; 62% relapsing-remitting MS; 13.7

2018 EvidenceUpdates

44. Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis Full Text available with Trip Pro

Diagnostic and Clinical Utility of the GAD-2 for Screening Anxiety Symptoms in Individuals With Multiple Sclerosis To assess the diagnostic and clinical utility of the 2-item Generalized Anxiety Disorder Scale (GAD-2) for screening anxiety symptoms in individuals with multiple sclerosis (MS).Cross-sectional.University-affiliated MS neurology and rehabilitation center.The sample comprised adults (N=99) (ages 19-72; mean ± SD=46.2±13.0; 75% women) with a physician-confirmed MS diagnosis who were

2018 EvidenceUpdates

45. Vitamin D for the management of multiple sclerosis. Full Text available with Trip Pro

Vitamin D for the management of multiple sclerosis. This review is an update of a previously published review, "Vitamin D for the management of multiple sclerosis" (published in the Cochrane Library; 2010, Issue 12). Multiple sclerosis (MS) is characterised by inflammation, demyelination, axonal or neuronal loss, and astrocytic gliosis in the central nervous system (CNS), which can result in varying levels of disability. Some studies have provided evidence showing an association of MS with low (...) levels of vitamin D and benefit derived from its supplementation.To evaluate the benefit and safety of vitamin D supplementation for reducing disease activity in people with MS.We searched the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Specialized Register up to 2 October 2017 through contact with the Information Specialist with search terms relevant to this review. We included references identified from comprehensive electronic database searches and from handsearches of relevant

2018 Cochrane

46. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. (Abstract)

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis. Treatment of patients younger than 18 years of age with multiple sclerosis has not been adequately examined in randomized trials. We compared fingolimod with interferon beta-1a in this population.In this phase 3 trial, we randomly assigned patients 10 to 17 years of age with relapsing multiple sclerosis in a 1:1 ratio to receive oral fingolimod at a dose of 0.5 mg per day (0.25 mg per day for patients with a body (...) ; relative difference, 82%; P<0.001). The key secondary end point of the annualized rate of new or newly enlarged lesions on T2-weighted magnetic resonance imaging (MRI) was 4.39 with fingolimod and 9.27 with interferon beta-1a (absolute difference, 4.88 lesions; relative difference, 53%; P<0.001). Adverse events, excluding relapses of multiple sclerosis, occurred in 88.8% of patients who received fingolimod and 95.3% of those who received interferon beta-1a. Serious adverse events occurred in 18

2018 NEJM Controlled trial quality: predicted high

47. Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. Full Text available with Trip Pro

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis.We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg (...) less brain-tissue loss with ibudilast over a period of 96 weeks. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression.In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT

2018 NEJM Controlled trial quality: predicted high

48. Tumefactive multiple sclerosis masquerade as a central nervous system tumor: a case report Full Text available with Trip Pro

Tumefactive multiple sclerosis masquerade as a central nervous system tumor: a case report Tumefactive multiple sclerosis is a demyelinating disorder that appears tumor-like on MRI. To most physicians, diagnosing tumefactive MS by applying clinical, radiological, or laboratory examination like Cerebrospinal fluid (CSF) analysis, can be challenging and ultimately biopsy is necessary to confirm the diagnosis.This paper reports a case of a 37-year-old woman who presented with progressive headache

2018 Electronic physician

49. Multiple sclerosis

Multiple sclerosis Top results for multiple sclerosis - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (...) (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for multiple sclerosis The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many

2018 Trip Latest and Greatest

50. Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial (Abstract)

Moderators of Treatment Outcomes After Telehealth Self-Management and Education in Adults With Multiple Sclerosis: A Secondary Analysis of a Randomized Controlled Trial To examine moderators of treatment effects in a randomized controlled trial comparing a telehealth self-management intervention with a telehealth multiple sclerosis (MS) education intervention for fatigue, pain, and mood in adults with MS.Secondary analysis of a single-blind randomized controlled trial.Community.Adults with MS

2018 EvidenceUpdates

51. Pharmacological treatment for memory disorder in multiple sclerosis

Pharmacological treatment for memory disorder in multiple sclerosis Pharmacological treatment for memory disorder in multiple sclerosis - He, D - 2013 | Cochrane Library Cookies Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in . Trusted evidence. Informed decisions. Better health (...) Collections Pharmacological treatment for memory disorder in multiple sclerosis Cochrane Systematic Review - Intervention Version published: 17 December 2013 New search Collapse all Expand all Abstract available in Background This is an update of the Cochrane review "Pharmacologic treatment for memory disorder in multiple sclerosis" (first published in The Cochrane Library 2011, Issue 10). Multiple sclerosis (MS) is a chronic immune‐mediated, inflammatory, demyelinating, neurodegenerative disorder

2018 European Academy of Neurology

52. Ocrelizumab for treating relapsing?remitting multiple sclerosis

Ocrelizumab for treating relapsing?remitting multiple sclerosis Ocrelizumab for treating Ocrelizumab for treating relapsing–remitting multiple sclerosis relapsing–remitting multiple sclerosis T echnology appraisal guidance Published: 25 July 2018 nice.org.uk/guidance/ta533 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guidance represent the view (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ocrelizumab for treating relapsing–remitting multiple sclerosis (TA533) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 22Contents Contents 1 Recommendations 4 2 Information about

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

53. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study Full Text available with Trip Pro

Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS).Patients (n = 232) were randomized to ofatumumab 3, 30, or 60 mg every 12 weeks, ofatumumab 60 mg every 4 weeks, or placebo for a 24-week treatment period, with a primary endpoint of cumulative number of new

2018 EvidenceUpdates Controlled trial quality: uncertain

54. Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis (Abstract)

Effectiveness of virtual reality training for balance and gait rehabilitation in people with multiple sclerosis: a systematic review and meta-analysis To evaluate the evidence for the use of virtual reality to treat balance and gait impairments in multiple sclerosis rehabilitation.Systematic review and meta-analysis of randomized controlled trials and quasi-randomized clinical trials.An electronic search was conducted using the following databases: MEDLINE (PubMed), Physiotherapy Evidence (...) outcomes of interest. A total of 466 participants clinically diagnosed with multiple sclerosis were analysed. Results showed that virtual reality balance training is more effective than no intervention for postural control improvement (standard mean difference (SMD) = -0.64; 95% confidence interval (CI) = -1.05, -0.24; P = 0.002). However, significant overall effect was not showed when compared with conventional training (SMD = -0.04; 95% CI = -0.70, 0.62; P = 0.90). Inconclusive results were also

2018 EvidenceUpdates

55. Multiple sclerosis

Multiple sclerosis Evidence Maps - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading

2018 Trip Evidence Maps

56. Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial (Abstract)

Investigating the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis: a randomized controlled trial To evaluate the combined effect of pelvic floor muscle exercise and mindfulness on sexual function in women with multiple sclerosis.It was a three-arm parallel randomized clinical trial study.Outpatient clinic.Patients with multiple sclerosis.Participants in the intervention groups completed an eight-week program consisting (...) obtained for the sexual function of mindfulness group were 19.5 ± 6.4, 26.9 ± 4.8, and 25.6 ± 4.5, respectively. Moreover, mean scores obtained for pelvic floor muscle exercise along with mindfulness were 19.6 ± 5.9, 25.3 ± 5.4, and 25 ± 4.8, respectively. There was no significant difference in their effects on sexual function ( P > 0.05).Mindfulness and pelvic floor muscle exercise do not have any significant impact upon sexual dysfunction of people with multiple sclerosis.

2018 EvidenceUpdates

57. Multiple sclerosis: a drug that should never have been authorised

Multiple sclerosis: a drug that should never have been authorised Prescrire IN ENGLISH - Spotlight ''Multiple sclerosis: a drug that should never have been authorised'', 1 July 2018 {1} {1} {1} | | > > > Multiple sclerosis: a drug that should never have been authorised Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Multiple sclerosis: a drug (...) that should never have been authorised In March 2018, after several deaths, daclizumab (Zinbryta°) was withdrawn from the market. The European Medicines Agency should never have authorised this drug. In patients with multiple sclerosis, interferon beta is the first-choice treatment, for want of a better option. Despite the severity of multiple sclerosis in some patients, there is no justification for exposing them to drugs such as alemtuzumab, natalizumab or teriflunomide, whose harm-benefit balance

2018 Prescrire

58. Beta interferons and glatiramer acetate for treating multiple sclerosis

Beta interferons and glatiramer acetate for treating multiple sclerosis Beta interferons and glatir Beta interferons and glatiramer acetate amer acetate for treating multiple sclerosis for treating multiple sclerosis T echnology appraisal guidance Published: 27 June 2018 nice.org.uk/guidance/ta527 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations (...) and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Beta interferons and glatiramer acetate for treating multiple sclerosis (TA527) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 29Contents Contents 1

2018 National Institute for Health and Clinical Excellence - Technology Appraisals

59. Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS)

Teriflunomide (Aubagio) - relapsing remitting multiple sclerosis (RRMS) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved

2018 Health Canada - Drug and Health Product Register

60. Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Full Text available with Trip Pro

Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology To review evidence on starting, switching, and stopping disease-modifying therapies (DMTs) for multiple sclerosis (MS) in clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and progressive MS forms.Relevant, peer-reviewed research articles, systematic

2018 EvidenceUpdates